MedTrace Logo

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-13

No results posted yet for this study

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Conditions

Interventions

DRUG

Psilocybin

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Sponsors & Collaborators

  • Joshua Woolley, MD, PhD

    lead OTHER

Principal Investigators

  • Joshua Woolley, MD,PhD · University of California, San Francisco

  • Ellen Bradley, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2027-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06455293 on ClinicalTrials.gov